NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On February7, 2017, the Supervisory Board (the Board) of Nabriva
Therapeutics AG (the Company), following approval and
recommendation from the Compensation Committee of the Board and
consistent with the recommendations of the independent
compensation consultant to the Compensation Committee, approved
the annual base salaries for 2017, performance-based bonus
payments for 2016 and annual equity awards of options to purchase
common shares of the Company under the Companys 2015 Stock Option
Plan to the Companys executive officers, as set forth below.
|
Name |
|
2017AnnualBaseSalary(1) |
|
2016Bonus |
|
StockOptions(2) |
|
|
Colin Broom Chief Executive Officer |
$457,800 |
$174,400 |
26,100 |
||||
|
Gary Sender Chief Financial Officer |
$360,500 |
$104,125 |
11,300 |
||||
|
Elyse Seltzer Chief Medical Officer |
$394,552 |
$108,594 |
11,300 |
||||
|
Steven Gelone Chief Development Officer |
$353,280 |
$93,731 |
11,300 |
(1)Effective as of January1, 2017.
(2)Each of these stock option awards has a grant date of
February7, 2017 and will vest over a four-year period beginning
on February28, 2017. Twenty-five percent (25%) of each option
award will vest on February28, 2018, and the remaining
seventy-five percent (75%) of each option award will vest on a
monthly pro-rata basis over the remaining vesting period. The
exercise price for these stock option awards is 79.63, which was
the euro equivalent of the closing sale price of the common
shares underlying the American Depositary Shares of the Company
on the NASDAQ Global Market on the grant date.
In addition, on February7, 2017, the Board approved the award of
a performance-based bonus payment for 2016 of $96,152 to the
Companys former General Counsel and Corporate Secretary, J. Peter
Wolf.
About NABRIVA THERAPEUTICS AG (NASDAQ:NBRV)
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH. NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Recent Trading Information
NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) closed its last trading session down -0.09 at 9.51 with 28,807 shares trading hands.
